ViCentra, manufacturer of the Kaleido insulin delivery system, today announced the appointment of Dr. David Kerr and Dr. Fred Storms as medical and scientific advisors to its team.
Drs. Kerr and Storms are both internationally recognised experts in the treatment of diabetes mellitus, and bring a wealth of expertise and knowledge of healthcare provision and diabetes management to ViCentra.
“I am delighted to welcome David and Fred as medical and scientific advisors to ViCentra,” said ViCentra CEO, Michael Graves. “They are both hugely passionate about the role technology can play in helping people living with diabetes, and securing their extensive collective knowledge, enthusiasm for medical technology that benefits the people that use it, and their professional guidance will be of huge benefit to us. We look forward to working with them both and drawing on their vast knowledge as we continue to clinically validate the Kaleido system, launch it into the European market and then look to the future, with the development of the next generation of ViCentra products”.
Dr. David Kerr, MBCHB, DM, FRCPE is Director of Research and Innovation at the William Sansum Diabetes Centre, California and Director of mHealth Services for the Diabetes Technology Society. He was previously Consultant Physician at the Bournemouth Diabetes and Endocrine Centre in the UK. Dr. Kerr’s research focuses on the use of technology in diabetes care and he is the creator and co-founder of Diabetes Travel and ExCarbs. He has also authored more than 200 peer-reviewed articles and has held an NHS Gold Clinical Excellence Award for many years. Dr. Kerr is interested in the role that new technologies can play in benefitting people with diabetes for the longest period of time and with the minimum disruption to their lives, something he recognizes that ViCentra’s products have the ability to do. He tweets at @GoDiabetesMD.
Dr. Fred Storms, MD, PhD is one of the Netherlands’ leading authorities on the treatment of diabetes mellitus. Medical Director of the Diabetes Care team at St. Antonius Hospital, Utrecht until his retirement in 2016, he has participated in multiple international studies, including AT.LANTUS, PROactive, ONTARGET and EMPA-REG, and contributed to several trials of leading insulin pump therapies. He serves as medical advisor to the Dutch Diabetes Association (DVN) and was previously a senior advisor at the Dutch Institute for Healthcare Improvement (CBO). Dr. Storms is excited by the possibilities presented by the accuracy and usability of the Kaleido insulin delivery system and its consumer-focused approach.
Dr. Kerr and Dr. Storms join ViCentra with immediate effect.